Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994-2018)
Journal of Veterinary Internal Medicine · 01.03.2023 · 37 (2) · 635-647
DOI: 10.1111/jvim.16644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.03.2023. Verfasst von Daniela Enache und 8 weiteren Autor:innen. Beteiligte Einrichtung: AniCura Istituto Veterinario Novara, Granozzo con Monticello (NO), Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Dog Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Few studies have assessed predictors of outcome in dogs with thyroid tumors undergoing thyroidectomy.
Objective
To estimate the survival and identify prognostic factors in dogs with thyroid tumors treated by thyroidectomy. Animals A total of 144 client-owned dogs with thyroid neoplasia that underwent thyroidectomy.
Methods
Retrospective study. Data for analysis included hospital attended and year of surgery, signalment, thyroxine concentration, thyroid tumor features (lobe involvement, size, invasiveness, histopathological type), thrombosis, metastasis, additional surgery and therapy, administration of adjuvant chemotherapy. The association of predictors with survival (time from surgery to death) were assessed by calculating cause-specific hazard ratios (HRcs) and 95% confidence intervals (CI). Causes of death were classified as thyroid-related or because of other cause.
Results
Overall median survival time was 802 days (CI95% = 723-1015 days); 89 dogs (77.4%) survived >500 days. Metastases were identified at admission in 12 (8.3%) dogs and were associated with higher thyroid cancer-related fatality (HR = 5.83, CI95% = 1.56-21.78; P = .009). Thrombosis occurred in 40 dogs and was associated with increased risk of death because of other cause (HR = 2.73, CI95% = 1.18-6.35; P = .019). Nonfollicular carcinoma (HR = 4.17, CI95% = 1.27-13.69; P = .018) and administration of chemotherapy (HR = 3.45, CI95% = 1.35-8.82; P = .01) were associated with higher risk of thyroid cancer-related death. Conclusions and Clinical Importance Dogs with thyroid tumors undergoing thyroidectomy have a long life expectancy. Despite the rare presence of nonfollicular carcinoma and metastases, thyroidectomy should still be considered in some of these dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AniCura Istituto Veterinario Novara, Granozzo con Monticello (NO), Italy.
- Dipartimento di Scienze Veterinarie, University of Turin, Grugliasco (TO), Italy.
- Clinica Veterinaria Nervianese, Nerviano (MI), Italy.
- Centro Specialistico Veterinario, Milan, Italy.
- Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Daniela Enache, Eric Zini
Zitieren
APA
Enache, D., Ferro, L., Morello, E. M., Massari, F., Romanelli, G., Nicoli, S., Guazzetti, S., Porporato, F., & Zini, E. (2023). Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994-2018). Journal of Veterinary Internal Medicine, 37(2), 635-647. https://doi.org/10.1111/jvim.16644
Vancouver
Enache D, Ferro L, Morello EM, Massari F, Romanelli G, Nicoli S, et al. Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994-2018). Journal of Veterinary Internal Medicine. 2023;37(2):635-647. doi:10.1111/jvim.16644
BibTeX
@article{Enache2023,
author = {Enache, Daniela and Ferro, Livia and Morello, Emanuela M and Massari, Federico and Romanelli, Giorgio and Nicoli, Stefano and Guazzetti, Stefano and Porporato, Federico and Zini, Eric},
title = {Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994-2018)},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
volume = {37},
number = {2},
pages = {635--647},
doi = {10.1111/jvim.16644}
}
EUVIMED